New variants are becoming refractory to both conva
Post# of 148278
“These findings suggest that antibody treatment of this virus might need to be modified in localities where B.1.351 and related variants13,14 are prevalent, and highlight the importance of combination antibody therapy to address the expanding antigenic diversity of SARS-CoV-2.”
“Mutationally, this virus is traveling in a direction that could ultimately lead to escape from our current therapeutic and prophylactic interventions directed to the viral spike. If the rampant spread of the virus continues and more critical mutations accumulate, then we may be condemned to chasing after the evolving SARS-CoV-2 continually, as we have long done for influenza virus. “
These are NIH, Columbia Med, Regeneron scientists.
https://www.nature.com/articles/s41586-021-03...erence.pdf